The Dog Aging Project, which began in 2014, has enrolled 50,000 dogs and is driving clinical trials and commercial efforts to extend healthy canine lifespans, including a rapamycin trial slated for 2026 and FDA approval for Loyal’s experimental drug LOY-002. Read On…
After a 2024 funding lapse, the Dog Aging Project has won a five-year, $7 million grant from the National Institute on Aging to expand its rapamycin trial involving 580 dogs, with enrollment set to finish by the end of the year and dosing slated for spring 2026. Read On…